Press Release
Stephen Bardin to Join atai Life Sciences as CFO Designate
Stephen Bardin will join as CFO Designate on June 27, 2022 After a transition period, atai’s current CFO Greg Weaver will be moving into a part time strategic advisory role NEW YORK and BERLIN, June 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V., (Nasdaq: ATAI) (“atai” or the “Company”), a
Press Release
atai Life Sciences to Participate in Upcoming June Healthcare Conferences
NEW YORK and BERLIN, June 16, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming healthcare conferences in June: BIO
Press Release
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update
– Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health – Key milestones include first subject dosed in Phase 1 KUR-101, launch of drug discovery engine Invyxis, initiation of Psyber
Press Release
CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued yesterday under the headline "atai Life Sciences to Announce First-Quarter 2022 Financial Results" by atai Life Sciences N.V. (Nasdaq: ATAI), please note the first and second paragraphs, which contained statements referencing the 2022
Press Release
atai Life Sciences to Participate in Upcoming April Investor Conference
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in April: Benzinga Psychedelics
Press Release
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
–   Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initiations with PCN-101,
Displaying 7 - 12 of 67